Corrections: Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (The Lancet Infectious Diseases (2016) 16(5) (565–575) (S1473309915005368) (10.1016/S1473-3099(15)00536-8));Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study

The Lancet Infectious Diseases

Volumn 16, Issue 5, 2016, Pages 565-575

  Gregson, J ^a,bd   Tang, M ^b,bd   Ndembi, N ^c,bd   Hamers, R L ^d,bd   Marconi, V C ^e,f,bd   Brooks, K ^h,bd   Theys, K ^i,bd   Arruda, M ^j,bd   Garcia, Frederico ^bd   Monge, Susana ^bd   Kanki, P J ^q,bd   Kumarasamy, N ^r,bd   Kerschberger, Bernard ^bd   Mor, O ^t,bd   Charpentier, C ^u,v,bd   Todesco, E ^w,bd   Rokx, C ^x,bd   Gras, L ^y,bd   Halvas, Elias K ^bd   Sunpath, H ^aa,bd   Carlo, Domenico Di ^bd   Antinori, Antonio ^bd   Andreoni, Massimo ^bd   Latini, Alessandra ^bd   Mussini, C ^af,bd   Aghokeng, A ^ag,bd   Sonnerborg, A ^ah,bd   Neogi, U ^ah,bd   Fessel, William J ^bd   Agolory, S ^aj,bd   Yang, C ^aj,bd   Blanco, Jose L ^bd   Juma, James M ^bd   Smit, E ^am,bd   Schmidt, D ^an,bd   Watera, C ^ao,bd   Asio, J ^ao,bd   Kirungi, W ^ap,bd   Tostevin, A ^aq,bd   Clumeck, N ^as,bd   Goedhals, D ^at,bd   Bester, Philip Armand ^bd   Sabin, C ^au,bd   Mukui, Irene ^bd   Santoro, M M ^ab,bd   Perno, C F ^ac,bd   Hunt, G ^aw,bd   Morris, L ^aw,bd   Pillay, D ^au,ax,bd   Schulter, E ^az,bd   Reyes Teran G ^bd   Romero, Karla ^bd   Avila Rios, Santiago ^bd   Sirivichayakul, S ^bb,bd   Ruxrungtham, K ^bb,bd   Mekprasan, S ^bb,bd   Dunn, D ^aq,bd   Kaleebu, P ^ao,bc,bd   Raizes, E ^aj,bd   Kantor, R ^i,bd   Gupta, R K ^au,bd   Rhee, S Y ^b   Shafer, R W ^b   de Wit, T F Rinke ^d   Diero, L ^g   Camacho, Ricardo ^bd   Gunthard H F ⁿ   Hoffmann, C J ^o,p   Di Carlo, D ^ab   El Hay, T ^ar   van Vuuren, C ^at   de Oliveira, T ^ax,ay   Murakami Ogasawara, A ^ba   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e EMORY UNIVERSITY   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^h BROWN UNIVERSITY   (United States)

ⁱ REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^j FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l UNIVERSITY OF ALCALÁ   (Spain)

^m CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁿ UNIVERSITY OF ZURICH   (Switzerland)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p AURUM INSTITUTE   (South Africa)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^r VHS Medical Centre India   (India)

^s MÉDECINS SANS FRONTIÈRES   (Switzerland)

^t MINISTRY OF HEALTH   (Israel)

^u UNIVERSITÉ PARIS DIDEROT   (France)

^v BICHAT HOSPITAL   (France)

^w PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^x ERASMUS MEDICAL CENTER   (Netherlands)

^y STICHTING HIV MONITORING   (Netherlands)

^z UNIVERSITY OF PITTSBURGH   (United States)

^aa Ethekwini District Health Office   (South Africa)

^ab UNIVERSITY OF ROME TOR VERGATA   (Italy)

^ac NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^ad TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^ae SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^af UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^ag Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^ah KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ai KAISER PERMANENTE   (United States)

^aj CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^ak INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^al National Tuberculosis and Leprosy Programme   (Tanzania)

^am PUBLIC HEALTH ENGLAND   (United Kingdom)

^an ROBERT KOCH INSTITUTE   (Germany)

^ao MRC UVRI Research Unit on AIDS   (Uganda)

^ap MINISTRY OF HEALTH   (Uganda)

^aq MRC CLINICAL TRIALS UNIT   (United Kingdom)

^ar IBM HAIFA RESEARCH LAB   (Israel)

^as SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^at UNIVERSITY OF THE FREE STATE   (South Africa)

^au UNIVERSITY COLLEGE LONDON   (United Kingdom)

^av MINISTRY OF HEALTH   (Kenya)

^aw NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^ax AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^ay UNIVERSITY OF KWAZULU NATAL   (South Africa)

^az UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^ba INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^bb CHULALONGKORN UNIVERSITY   (Thailand)

^bc MEDICAL RESEARCH COUNCIL   (United Kingdom)

^bd NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTASE GENE; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GLOBAL HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; EMTRICITABINE; GLOBAL HEALTH; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; PRE-EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; VIRAL LOAD;

EID: 84955570289     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30723-5     Document Type: Erratum

References (32)

1. World AIDS Day 2014 Report - fact sheet UNAIDS, (accessed May 7, 2015). http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014/factsheet.
2. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013 WHO, (accessed July 14, 2015). http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.
3. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
4. Hankins CA, Dybul MR The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 2013, 8:50-58.
5. Garforth SJ, Lwatula C, Prasad VR The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance. Viruses 2014, 6:4080-4094.
6. Margot NA, Lu B, Cheng A, Miller MD Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006, 7:442-450. the Study 903 Team.
7. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009, 52:209-221. the Study 934 Team.
8. Bulteel N, Bansi-Matharu L, Churchill D, et al. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect 2014, 68:77-84. the UK Collaborative HIV Cohort (CHIC) Study Group, the UK HIV Drug Resistance Database (UK HDRD) Study Groupthe UK HIV Drug Resistance Database (UK HDRD) Study Group.
9. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 2012, 26:1679-1684.
10. Etiebet MA, Shepherd J, Nowak RG, et al. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS 2013, 27:553-561.
11. Wensing AM, Calvez V, Gunthard HF, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2014, 22:642-650.
12. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009, 361:2230-2240. the AIDS Clinical Trials Group Study A5202 Team.
13. Weber J, Chakraborty B, Weberova J, Miller MD, Quiñones-Mateu ME Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005, 43:1395-1400.
14. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009, 49:1928-1935.
15. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010, 201:1303-1307.
16. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
17. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 380:1250-1258.
18. Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother 2015, 70:2693-2708.
19. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 2012, 54(suppl 4):S280-S289.
20. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006, 296:679-690.
21. O'Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis 2013, 208:40-49. the INSIGHT SMART Study Group.
22. Mollan K, Daar ES, Sax PE, et al. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis 2012, 206:1920-1930. the AIDS Clinical Trials Group Study A5202 Team.
23. Ford N, Meintjes G, Pozniak A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis 2015, 15:241-247.
24. Rokx C, Fibriani A, van de Vijver DA, et al. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin Infect Dis 2015, 60:143-153.
25. Ford N, Shubber Z, Hill A, et al. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One 2013, 8:e79981.
26. Tang MW, Kanki PJ, Shafer RW A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012, 54:862-875.
27. Mesplède T, Wainberg MA Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses 2015, 7:3703-3718.
28. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005, 191:1403-1409.
29. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929. the Rakai Project Study Group.
30. Chan PA, Huang A, Kantor R Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis. J Int AIDS Soc 2012, 15:17701.
31. Boender TS, Sigaloff KC, McMahon JH, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 2015, 61:1453-1461.
32. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009, 200:1202-1206.